Needham & Company maintains a 'Buy' on Lexicon Pharmaceuticals (NASDAQ: LXRX).

Analyst, Alan Carr, said, "We do not believe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE